Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lecia Vandam Sequist, M.D.

Co-Author

This page shows the publications co-authored by Lecia Sequist and Zofia Piotrowska.
Connection Strength

11.612
  1. Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018 10 01; 29(10):2092-2097.
    View in: PubMed
    Score: 0.886
  2. Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
    View in: PubMed
    Score: 0.885
  3. Piotrowska Z, Hazar-Rethinam M, Rizzo C, Nadres B, Van Seventer EE, Shahzade HA, Lennes IT, Iafrate AJ, Dias-Santagata D, Leshchiner I, Jessop NA, Hu H, Digumarthy SR, Nagy RJ, Lanman RB, Moody S, Niederst MJ, Engelman JA, Hata AN, Corcoran RB, Sequist LV. Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.873
  4. Piotrowska Z, Stirling K, Heist R, Campo M, Rizzo C, Digumarthy SR, Lanuti M, Fintelmann FJ, Lennes I, Farago A, Gainor J, Azzoli CG, Temel J, Mino-Kenudson M, Dias-Santagata D, Corcoran R, Shaw A, Engelman JA, Hata A, Sequist LV. Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):220.
    View in: PubMed
    Score: 0.803
  5. Piotrowska Z, Sequist LV. Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer. J Thorac Oncol. 2017 03; 12(3):419-421.
    View in: PubMed
    Score: 0.794
  6. Piotrowska Z, Sequist LV. Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review. JAMA Oncol. 2016 Jul 01; 2(7):948-54.
    View in: PubMed
    Score: 0.758
  7. Piotrowska Z, Drapkin B, Engelman JA, Nagy RJ, Lanman RB, Sequist LV. Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer. J Thorac Oncol. 2016 08; 11(8):e95-e97.
    View in: PubMed
    Score: 0.747
  8. Piotrowska Z, Sequist LV. Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand? Oncologist. 2015 Nov; 20(11):1230-2.
    View in: PubMed
    Score: 0.723
  9. Piotrowska Z, Sequist LV. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options. Cancer J. 2015 Sep-Oct; 21(5):371-7.
    View in: PubMed
    Score: 0.716
  10. Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, Parks MK, DiCecca RH, Dias-Santagata D, Iafrate AJ, Shaw AT, Allen AR, Engelman JA, Sequist LV. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov. 2015 Jul; 5(7):713-22.
    View in: PubMed
    Score: 0.699
  11. Piper-Vallillo AJ, Sequist LV, Piotrowska Z. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. J Clin Oncol. 2020 Jun 18; JCO1903123.
    View in: PubMed
    Score: 0.249
  12. Dagogo-Jack I, Piotrowska Z, Cobb R, Banwait M, Lennerz JK, Hata AN, Digumarthy SR, Sequist LV. Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. J Thorac Oncol. 2019 10; 14(10):e226-e228.
    View in: PubMed
    Score: 0.237
  13. Digumarthy SR, Mendoza DP, Padole A, Chen T, Peterson PG, Piotrowska Z, Sequist LV. Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer. Cancers (Basel). 2019 Sep 13; 11(9).
    View in: PubMed
    Score: 0.237
  14. Fintelmann FJ, Troschel FM, Kuklinski MW, McDermott S, Petranovic M, Digumarthy SR, Sharma A, Troschel AS, Price MC, Hariri LP, Gilman MD, Shepard JO, Sequist LV, Piotrowska Z. Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer. Oncologist. 2019 12; 24(12):1570-1576.
    View in: PubMed
    Score: 0.232
  15. Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285.
    View in: PubMed
    Score: 0.225
  16. Piotrowska Z, Fintelmann FJ, Sequist LV, Jahagirdar B. Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma. J Thorac Oncol. 2018 10; 13(10):e204-e206.
    View in: PubMed
    Score: 0.222
  17. Khandekar MJ, Piotrowska Z, Willers H, Sequist LV. Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers. Oncologist. 2018 09; 23(9):1054-1062.
    View in: PubMed
    Score: 0.215
  18. Mooradian MJ, Piotrowska Z, Drapkin BJ, Dias-Santagata D, Marcoux N, Arnaoutakis K, Nagy RJ, Lanman R, Iafrate AJ, Farago AF, Mino-Kenudson M, Hata AN, Sequist LV. Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.208
  19. Farago AF, Piotrowska Z, Sequist LV. Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma. J Clin Oncol. 2017 09 10; 35(26):2987-2988.
    View in: PubMed
    Score: 0.203
  20. Dagogo-Jack I, Sequist LV, Piotrowska Z. The Role of Liquid Biopsies in Lung Cancer Screening. Semin Roentgenol. 2017 Jul; 52(3):185-187.
    View in: PubMed
    Score: 0.202
  21. Sequist LV, Piotrowska Z, Niederst MJ, Heist RS, Digumarthy S, Shaw AT, Engelman JA. Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. JAMA Oncol. 2016 Apr; 2(4):541-3.
    View in: PubMed
    Score: 0.186
  22. Al-Halabi H, Sayegh K, Digamurthy SR, Niemierko A, Piotrowska Z, Willers H, Sequist LV. Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy. J Thorac Oncol. 2015 Nov; 10(11):1601-7.
    View in: PubMed
    Score: 0.181
  23. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1700-9.
    View in: PubMed
    Score: 0.175
  24. Piotrowska Z, Scribner E, Temel B, Heist RS, Sequist LV, Temel JS. Retrospective chart review of end-of-life (EOL) care in patients with metastatic lung cancer harboring EGFR mutations. J Clin Oncol. 2014 Nov; 32(31_suppl):126.
    View in: PubMed
    Score: 0.169
  25. Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB. Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2020 May 01; 26(9):2277.
    View in: PubMed
    Score: 0.062
  26. Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, Hafeez N, Bilton SJ, Drier Y, Ji F, Greenberg M, Williams A, Kattermann K, Damon L, Sovath S, Rakiec DP, Korn JM, Ruddy DA, Benes CH, Hammerman PS, Piotrowska Z, Sequist LV, Niederst MJ, Barretina J, Engelman JA, Hata AN. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene. 2019 09; 38(37):6399-6413.
    View in: PubMed
    Score: 0.059
  27. Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, Settleman JE, Engelman JA, Hata AN, Willers H. Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. Cell Rep. 2019 06 18; 27(12):3422-3432.e4.
    View in: PubMed
    Score: 0.058
  28. Grassberger C, McClatchy D, Geng C, Kamran SC, Fintelmann F, Maruvka YE, Piotrowska Z, Willers H, Sequist LV, Hata AN, Paganetti H. Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. Cancer Res. 2019 07 15; 79(14):3776-3788.
    View in: PubMed
    Score: 0.058
  29. Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov. 2018 12; 8(12):1598-1613.
    View in: PubMed
    Score: 0.055
  30. Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2018 12 15; 24(24):6548-6555.
    View in: PubMed
    Score: 0.055
  31. Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.055
  32. Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK, Fintelmann FJ, Rizzo C, Piotrowska Z, Shaw AT, Gainor JF, Sequist LV, Niederst MJ, Engelman JA, Benes CH. Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. Cell Rep. 2017 Dec 12; 21(11):3298-3309.
    View in: PubMed
    Score: 0.052
  33. Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, Hicks MA, Hu H, Mulvey HE, Drier Y, Heisey DAR, Hughes MT, Patel NU, Lockerman EL, Garcia A, Gillepsie S, Archibald HL, Gomez-Caraballo M, Nulton TJ, Windle BE, Piotrowska Z, Sahingur SE, Taylor SM, Dozmorov M, Sequist LV, Bernstein B, Ebi H, Engelman JA, Faber AC. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. Clin Cancer Res. 2018 01 01; 24(1):197-208.
    View in: PubMed
    Score: 0.052
  34. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M. Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016 11 14; 7:13513.
    View in: PubMed
    Score: 0.049
  35. Bauman JR, Piotrowska Z, Muzikansky A, Gallagher E, Scribner E, Temel B, Sequist LV, Heist RS, Temel JS. End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations. J Palliat Med. 2016 12; 19(12):1316-1319.
    View in: PubMed
    Score: 0.048
  36. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016 06 10; 7:11815.
    View in: PubMed
    Score: 0.047
  37. Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016 Sep 15; 22(18):4585-93.
    View in: PubMed
    Score: 0.047
  38. Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, Lee D, Keating CL, Ruddy DA, Damon LJ, Crystal AS, Costa C, Piotrowska Z, Bardelli A, Iafrate AJ, Sadreyev RI, Stegmeier F, Getz G, Sequist LV, Faber AC, Engelman JA. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016 Mar; 22(3):262-9.
    View in: PubMed
    Score: 0.046
  39. Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin Cancer Res. 2015 Sep 01; 21(17):3924-33.
    View in: PubMed
    Score: 0.044
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.